Predicting Immunotherapy Benefit in Lung Cancer and Beyond With Ofer Sharon, MD

In this interview from the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Oncology Data Advisor speaks with Dr. Ofer Sharon, CEO of OncoHost. Dr. Sharon shares more about OncoHost’s poster presentation entitled “A Plasma-Based Proteomic Platform for Predicting Clinical Benefit From Immune Checkpoint Inhibitors in Multiple Cancers,” including:

  • Unmet needs regarding selection of patients who are likely to benefit from immunotherapy
  • OncoHost’s PROphet platform, a commercially available pretreatment plasma proteomic test that predicts clinical benefit and guides treatment decisions for first-line PD-(L)1 inhibitor–based therapy in patients with metastatic non–small cell lung cancer (NSCLC)
  • Their study investigating PROphet’s broader clinical utility by testing its predictive capabilities across diverse cancer types, including metastatic melanoma and HPV-related cancers
  • PROphet’s efficacy in these patient populations and next steps for analyzing additional patient samples to inform treatment decisions
  • How PROphet fits into the advancing landscape of precision oncology
  • And more!

About Dr. Sharon

Ofer Sharon, MD, is a physician and entrepreneur with over two decades of experience in clinical research, pharmaceuticals, and biotechnology. He has made vital contributions to the acceleration of personalized medicine and oncology drug development. Dr. Sharon is the CEO of OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes. Prior to joining OncoHost, Dr. Sharon served multiple roles in global pharmaceuticals, including AstraZeneca and Merck, and he was part of the pembrolizumab clinical development and launch team. He has co-founded several healthcare companies centered on bioinformatic and machine learning platforms for clinical deterioration detection and early intervention.

Related Articles


Your email address will not be published. Required fields are marked *